Monoamine oxidase A (MAOA) is an enzyme that catalyzes the degradation of dopamine, noradrenaline, and serotonin. Regulation of monoamine neurotransmitter abundance through MAOA activity strongly affects motor control, emotion, and cognitive function. Mutations in MAOA cause Brunner Syndrome, which is characterized by impulsive aggressive behavior and mild intellectual disability (ID). The impaired MAOA activity in Brunner Syndrome patients results in bioamine aberration, but it is currently unknown how this affects neuronal function. MAOA is highly expressed in serotonergic and dopaminergic neurons, and dysfunction of both neurotransmission systems is associated with aggressive behavior in mice and humans. Research has so far mainly focused on the serotonergic system. Here, we generated human induced pluripotent stem cell-derived induced dopaminergic neurons (iDANs) from individuals with known MAOA mutations, to investigate MAOA-dependent effects on dopamine neuronal function in the context of Brunner Syndrome. We assessed iDAN lines from three patients and combined data from morphological analysis, gene expression, single-cell electrophysiology, and network analysis using micro-electrode arrays (MEAs).
Introduction
Monoamines, such as dopamine and serotonin, have an important role in brain function, and dysregulation of monoaminergic pathways is associated with several mental disorders including schizophrenia, autism spectrum disorder, and attention deficit/hyperactivity disorder (ADHD) 1 . The abundance of monoamines is tightly regulated by monoamine oxidases (MAOs), which catabolize the monoaminergic neurotransmitters 2 . Disruption of MAO activity can thus have profound consequences on normal brain function 3 . Brunner Syndrome is a neurodevelopmental disorder characterized by hemizygous mutation of the X-linked monoamine oxidase, and was first described in a large Dutch kindred with non-dysmorphic borderline intellectual disability (ID) and prominent impulsive aggressive behavior 4, 5 . Recently, three more families have been reported in which affected individuals have Brunner Syndrome and carry either nonsense or missense mutations of MAOA 6,7 , which strengthens the association between MAOA dysfunction and Brunner Syndrome.
Changes in monoaminergic regulation, especially of serotonin and dopamine, have also been associated with aggressive behavior in animal models, both in wild-type animals [8] [9] [10] [11] as well as in genetic models for neurodevelopmental disorders 12 . Transgenic mouse models of Maoa have allowed the exploration of mechanistic associations between monoamine regulation and aggressive behavior.
Hemizygous Maoa mutant mice show abnormally high levels of aggressive behavior and disturbed monoamine metabolism, similar to the patient situation [13] [14] [15] . Maoa-deficient mice also display alterations in brain development, with aberrant organization of the primary somatosensory cortex 13 and increased dendritic arborization of pyramidal neurons in the orbitofrontal cortex 15 . Furthermore, Maoa has been implicated in the regulation of synaptic neurotransmitter receptors, as Maoa knockout mice show increased N-methyl-D-aspartate (NMDA) receptor subunit expression in the prefrontal cortex 16 .
Taken together, these data suggest that Maoa can influence both structural and functional aspects of neurodevelopment.
MAOA is expressed in different neuronal as well as glial cell types in the brain 17 . However, not all of these cell types are thought to be associated with the behavioral phenotypes observed in MAOA mutation carriers. So far, particular emphasis has been given to the serotonergic system in MAOA research, but MAOA is also abundantly expressed in dopaminergic neurons 18, 19 , and aggressive behavior is highly associated with aberrant dopamine pathway function 1, 20 . The current advances in the generation of human pluripotent stem cell (iPSC)-induced neurons (iNeurons) enable us to generate a homogenous culture of a single neuronal cell type. We therefore generated iPSC-derived induced dopaminergic neurons (iDANs), which offer a unique opportunity to investigate the cellular and molecular mechanisms specifically affected by MAOA dysfunction in dopaminergic neurons. We generated iDANs from three independent male individuals with unique MAOA mutations and from two independent male controls. Combining data from morphological analysis, gene expression, single-cell electrophysiology, and network analysis using micro electrode arrays (MEAs), we suggest that alterations in dopaminergic neuron development and function may also be relevant to behavioural and cognitive dysfunction in Brunner Syndrome.
Results

Generation of control and Brunner Syndrome patient-derived iDANs
Using a protocol adapted from 21 , we successfully differentiated iPSCs into iDANs after 55 days in vitro (DIV55, Figure 1a ). We generated iDANs from two independent control (control-1 and control-2) and three independent patient iPSC lines (Patient-NE8, c.886C>T, p.Q296*; Patient-ME8, c.797_798delinsTT, p.C266F; Patient-ME2, c.133C>T, p.R45W; Figure 1b , for extended information see Supplementary Table S2 ). Neuronal identity was confirmed by microtubule-associated protein 2 (MAP2) expression and iDAN identity by expression of tyrosine hydroxylase (TH) (Figure 1c) . Cell type specificity was comparable between lines, with more than 90% of MAP2-expressing neurons staining positive for TH (Figure 1d) . Interestingly, mRNA levels of MAOA were only altered compared to the healthy controls in the Patient-NE8 line, which has a nonsense mutation (Figure 1e) . The observed reduction might have been caused by nonsense-mediated mRNA decay, as shown earlier in human fibroblasts with the same mutation 25 . We used these five lines in subsequent experiments to investigate how MAOA dysfunction affects iDAN development and function.
Mutation-specific effects of MAOA-disruption on iDAN morphology
Dendritic properties of neurons in the orbitofrontal cortex are known to be altered in Maoa hemizygous knockout mice 15 . To assess whether MAOA dysfunction also affects the morphology of iDANs, we compared dendritic properties and soma size of control and patient iDANs by quantitative morphometric analysis of the somatodendritic compartment. ME8, NE8 and ME2 patient lines revealed mutation-dependent effects on iDAN morphology. Only iDANs with ME8 mutation showed increases in soma size (Figure 2b ) and dendrite complexity (Figure 2c,d ,e,f). Additionally, iDANs with the ME8 and ME2 mutations showed a significant increase in total covered surface (Convex Hull analysis, Figure 2g ), whilst iDANs with the NE8 mutation showed no differences in neuronal complexity. Next, we investigated if these differences in morphology could affect the number of excitatory synapses present on iDANs, since changes in neuronal complexity 26, 27 and synapse density 28 are widely associated with neurodevelopmental disorders. Indeed, synapse density was significantly decreased in iDANs from all patients compared to those from control-1 (Figure 2h, i) . This suggests that differences in synapse density might be caused by a molecular mechanism affected across mutations, whereas the drastic difference in iDAN dendritic morphology might be mutation-specific.
MAOA dysfunction leads to increased NMDAR expression in iDANs
The alterations in morphology and synapse density in MAOA hemizygous mutation iDANs prompted us to investigate whether gene expression of synapse-specific genes might be affected by MAOA dysfunction. In excitatory neurons, both α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and N-methyl D-aspartate receptors (NMDARs) are especially relevant for glutamatergic synaptic neurotransmission. Both AMPARs and NMDARs are heteromeric ion channels comprised of four subunits, and the ion channel composition conveys differences in ion selectivity as well as opening and closing kinetics. We therefore investigated the expression of the four main isoforms of the AMPA receptor subunits GluA1, 2, 3 and 4 (encoded by GRIA1, 2, 3, and 4, respectively) as well as the expression of the NR1, NR2A, and NR2B subunits (encoded by GRIN1, 2A and 2B, respectively) of the NMDA receptor.
When we compared control iDANs at DIV73 to our patient-derived iDANs, no difference in AMPAR subunit expression was seen (Figure S3a-d) . This suggests AMPAR-mediated neurotransmission is not affected in dopaminergic neurons by mutations in MAOA. Following evidence from Maoa knockout mice showing that NMDAR expression is altered in the prefrontal cortex 16 , we also investigated NMDAR in our patient-derived iDANs compared to controls. No difference in gene expression was found for GRIN1 (Figure 3a) , but increased expression was seen for both GRIN2A and GRIN2B in the patient-derived iDANs (Figure 3b,c) , similar to the earlier observations in Maoa knockout mice 16 .
Together, this data suggests that excitatory neurotransmitter receptor expression at the synapse is altered by MAOA dysfunction.
Intrinsic properties and AMPAR-mediated excitatory activity are not affected by MAOA mutation
As NMDAR expression is tightly linked to burst firing in dopaminergic neurons 29 and since differences in neuronal morphology and synapse density, as we observed them, can have drastic consequences for neuronal activity, we next explored if physiological activity is altered by MAOA dysfunction in iDANs. First, we explored whether MAOA dysfunction affects synapse physiology through altered excitatory neuron function using whole-cell patch clamp. Comparing the intrinsic properties of the control lines, we found no significant differences between control-1 and control-2 (Figure 4a-d) and
pooled the data for comparison with the patient-derived lines. No differences in intrinsic properties were observed between the pooled data of the control lines and the three patient lines (Figure 4e-h) .
To assess whether AMPAR-mediated inputs are affected by MAOA dysfunction, we measured spontaneous excitatory postsynaptic currents (sEPSCs). Again, we first compared control lines and found no differences in sEPSC amplitude or frequency (Figure 4i-k) . Comparison of the pooled control data to data from the individual patients revealed that AMPAR-mediated excitatory activity was not affected by mutations in MAOA (Figure 4i ,l,m); these findings are consistent with the absence of differences in the expression of GluA subunit mRNA between patients and controls.
MAOA dysfunction leads to increased iDAN network activity recorded by MEA
Since we found no differences in intrinsic properties and spontaneous AMPAR-driven activity at the single cell level, we next explored whether the increased NMDAR mRNA expression in MAOA-mutant iDAN lines leads to changes in neuronal activity at the network level. Therefore, we measured network activity of iDANs with MEA. Spontaneous random activity was clearly visible for all five iDAN cell lines at DIV73 (Figure 5a) , and robustly higher mean firing rates were seen for all patient lines compared to the activity in both control lines (Figure 5b,c) . Furthermore, whilst the control lines exhibited almost no coordinated network bursts, these were clearly visible in each of the patient-derived lines (Figure 5a , colored blocks in traces), and their frequency was significantly higher (Figure 5d,e ). This suggests that both missense and nonsense mutations of MAOA lead to increased activity in excitatory dopaminergic neurons, possibly through upregulation of NMDAR-driven network excitation.
Discussion
Dysfunction of MAOA in humans results in Brunner Syndrome. Here, we investigated Brunner Syndrome in a human iPSC-derived neuronal model for the first time, choosing dopaminergic neurons as our model. We generated two control and three patient lines and compared morphology, expression of synaptic genes, and neuronal physiology at the single-cell and network level. Confirming findings obtained in a Maoa knockout mouse model 15, 16 , we found neuronal complexity to be higher in dopaminergic neurons derived from humans carrying MAOA mutations. Our work further extends current knowledge by showing that such differences are mutation-dependent, as the p.C266F mutation (ME8) showed the strongest differences in iDAN morphology, whereas in the p.Q296* (NE8) line such alterations were less severe, and no differences were seen in the p.R45W (ME2) line. This suggests that different mutations might uniquely affect the function of the MAOA, as has been hypothesized in in vitro studies of MAOA function 30 . In addition to the mutation-specific effects on neuronal morphology, we observed several differences in neuronal function shared amongst all mutations. Firstly, we observed an increase in NMDAR mRNA expression, whilst AMPAR mRNA levels were unchanged. While intrinsic properties and spontaneous activity of single cells were unaffected, neuronal activity at the network level was robustly higher in all patient-derived lines compared to control iDANs.
The differences in spontaneous activity and in NMDAR expression could be related. Firstly, it has been shown that in Maoa knockout mice NMDAR expression is increased, which affects NMDARdependent currents in prefrontal cortex ex vivo slice preparations of these mice 16 . Furthermore, increased NMDAR-expression is able to enhance spontaneous neuronal activity during development 31 , and dysfunctional enhancement of NMDAR signaling has been described in other neurodevelopmental disorders 32 . However, how MAOA mutation and increased NMDAR expression are related on a mechanistic level needs to be further explored.
Synapse density was found reduced across patient-derived lines. This could be seen a compensatory mechanism in the case of the higher neuronal complexity in the ME8 patient line, but this cannot explain the reduced synapse density in the other patient lines. The expression and localization of NMDARs has been shown to regulate dendritic arborization [33] [34] [35] . It is therefore conceivable that the increased dendrite complexity and the changes in synapse density in the MAOA-mutant lines can be partially explained by the increased NMDAR expression. This study should be viewed in the context of its strengths and limitations. This is the first study on Brunner Syndrome investigating the molecular, cellular, and circuit alterations underlying the phenotype of the patients in iPSC-derived homogeneous neuronal cultures. The wide range of methods used and the integration of findings allowed us to validate results of animal models and extend our insight into the biological underpinnings of Brunner Syndrome further.
In conclusion, we established iDANs as a pure iPSC-derived human neuron culture that can be used to investigate disorders, which specifically affect monoaminergic pathways. Our data on MAOA dysfunction using this tool suggest that dopaminergic neurons may also be altered in humans carrying MAOA mutations, extending research focused on the serotonergic system. We confirm work performed in rodent models and non-neuronal transgenic models and extend such knowledge further by identifying both mutation-specific as well as general effects of MAOA dysfunction. Our findings of altered network activity may also link to human MRI studies showing altered structural and functional networks in carriers of a functional polymorphism in the MAOA gene. Beyond investigation of the biological underpinnings of neurodevelopmental disorders like Brunner Syndrome, the infrastructure we built may also provide a platform to investigate potential (individualized) therapeutic interventions for disorders in which monoamine regulation is disrupted.
Materials and Methods
Cell Culture of iPSCs
The iPSC line control-1 was derived from a dermal fibroblast biopsy of a male healthy volunteer. iPSC line control-2 was obtained from 50 and was generated from a healthy male donor using an episomal reprogramming 51 . The iPSC lines patient-NE8, patient-ME8 and patient-ME2 that carry MAOA mutations were derived from dermal fibroblast biopsies of male patients described previously 4-7 . The fibroblasts were reprogrammed by introducing four Yamanaka factors: Sox2, Klf4, Oct4, c-Myc via a lentivirus-based method. All iPSC reprogramming was done by the Radboudumc Stem Cell Technology Center (SCTC). iPSC pluripotency was characterized by immunocytochemistry and qPCR (supplemental figure S1). The iPSCs were maintained in Essential 8 complete medium with 100 µg/ml penicillin/streptomycin or 100 µg/ml Primocin (InvivoGen) on vitronectin (VTN-N)-coated cell culture plates (Corning) at 37˚C/5% CO2. Cell colonies were passaged by 0.5 mM ultrapure EDTA treatment for 2 or 3 minutes in DPBS without calcium and magnesium. Unless indicated otherwise, all the reagents were bought from Thermo Fisher Scientific Inc.
Differentiation of iPSCs into dopaminergic neurons
The iPSC colonies were split into single cells by Accutase treatment for 5 min at 37 o C two days before starting the differentiation, and 1-2x 10 4 /cm 2 cells were replated on a vitronectin-coated plate in Essential 8 complete medium supplemented with either 2uM thiazovivin(Sigma) or 1X RevitaCell Supplement. The differentiation protocol of dopaminergic neurons from iPSCs was modified from 21 .
From day 0 to day 5, the E8 complete medium was replaced with Knockout DMEM, supplemented with 15% Knockout Serum Replacement, 1x GlutaMAX, 100U/mL Penicillin-Streptomycin and 1x
MEM-NEAA. The 0.1mM β -Mercaptoethanol was added freshly before changing the medium. From day 6 to day 9, the Knockout DMEM medium was gradually replaced by 25%, 50%, 75% and 100% N2 medium (DMEM/F12 with 1x N-2 supplement) respectively. The iDANs were cultured in N2 medium until day 11. From day 12 on, the iDANs were cultured in neurobasal medium supplemented with 1x B27 and 1x GlutaMAX and half medium was refreshed every two days. During the differentiation and lineage specification, different combinations of small molecules and/or growth factors were added at different time points: 10µM LDN-193189 (Stemgent Inc.) from day 1 to day 11;
10µM SB431542 (Stemgent Inc.); from day1 to day 5; 2µM Purmorphamine (Stemgent Inc.); from day 1 1 day 2 to day 11; 3µM CHIR99021 (Stemgent Inc.); from day 3 to day 12; 100ng/ml recombinant human sonic hedgehog (C24II, SHH, R&D system); From day 12 to the end of the differentiation, 20ng/ml recombinant brain derived neurotrophic factor (BDNF, Peprotech), 20ng/ml recombinant glialderived neurotrophic factor (GDNF, Peprotech), 0.5mM adenosine 3',5'-cyclic monophosphate (cAMP, Enzo Life Science), 2ng/ml transforming growth factor beta 3 (TGFβ3, Millipore), 200µM ascorbid acid (AA, Sigma) and 10nM γ -secretase inhibitor IX (DAPT, Millipore, Calbiochem) were added into the medium. The cells were passaged only when they were 100% confluent using accutase. At day 20, the iDANs were split into single cells and 1-2x 10 4 /cm 2 cells were replated on a poly-L-ornithine (Sigma, 50 µg/ml) and murine Laminin (Sigma, 10 µg/ml) double-coated plate. From day 22 on, 10µM
DAPT was used to promote iDAN maturation. Rat astrocytes (prepared and plated according to 22 ) were cocultured with iDANs from day 24 to further promote maturation.
Gene expression analysis
To analyze the gene expression profile, the RNA was isolated from iPSCs and differentiated neurons with the RNeasy Mini Kit ( Na 2 -ATP, 0.4 Na 3 -ATP, 10 Na-phosphocreatine, 0.6 EGTA (adjusted to pH 7.25 and osmolarity 290 mosmol). Activity was recorded using a Digidata 1440A digitizer and a Multiclamp 700B amplifier (Molecular Devices). Sampling rate was set at 20KHz and a lowpass 1KHz filter was used during recording. Series resistance was monitored on-line and cells were discarded if series resistance increased above 1:10 of membrane resistance.
Spontaneous postsynaptic currents
sEPSCs were recorded in drug free recording medium at a holding potential of -60mV.
Intrinsic properties
Intrinsic properties were recorded in drug free medium. Current-voltage responses were recorded by 1 second stepwise injection of current in 5 pA increments. Current injection continued until clear action potentials were visible or until a maximum current of 100 pA was injected. Intrinsic properties were calculated off-line using Clampfit 10.7 software (Molecular Devices, San Jose, CA). Statistical comparison was conducted in PRISM (Graphpad PRISM 7.00, Graphpad Software, San Diego, CA).
Neuronal morphology reconstruction and data analysis
Wide field fluorescent images of the fixed and MAP2-labelled iPSC derived dopaminergic neurons were taken at 20x magnification using ApoTome microscopy (Zeiss Axio Imager Z1/Z2). The images were stitched using Fiji 2017 software with the stitching plugin and digitally reconstructed using Genotyping of the MAOA promoter VNTR polymorphism: The genomic DNA was amplified with 1x
AmpliTaq Gold® 360 Master Mix (Life Technologies) and 0.33 mM of fluorescently labeled forward primer (FAM-5'-ACAGCCTGACCGTGGAGAAG-3′) and reverse primer (5′-GAACGGACGCTCCATTCGGA-3′) in a total volume of 7,5µl using the protocol: 95⁰C for 10 min followed by 35 cycles of denaturation for 30 s at 95⁰C, 30 s annealing at 60⁰C, primer extension at 72⁰C for 1min and a final extension at 72⁰C for 10 min. Fragment length analysis of the PCR product was performed by an automated capillary sequencer ABI3730 (Applied Biosystems, Nieuwerkerk a/d Ijssel, The Netherlands) using standard conditions (1 ul of the 1:20 diluted PCR product together with 9.7 ul formamide and 0.3ul GeneScan-600 Liz Size Standard TM (Applied Biosystems, Nieuwekerk aan den Ijsel, the Netherlands). Results were analyzed with GeneMarker version 2.6.7 (SoftGenetics, US).
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